ESRD Corporate Compliance & False Claims Act Risk Management

ESRD Corporate Compliance & False Claims Act Risk Management

The dialysis sector has been one of the most active areas of False Claims Act enforcement in healthcare, with major settlements involving the largest national dialysis providers and a consistent OIG Work Plan presence reflecting sustained federal enforcement interest in dialysis billing and clinical practices. A functioning compliance program is your most important tool for detecting problems before federal investigators do. We build compliance programs that function as intended — not ones that exist on paper.

Overview

The False Claims Act exposure for dialysis operators arises from multiple directions — clinical documentation practices that do not support the services billed, EPO and other medication dosing and documentation practices, facility-physician financial arrangement compliance, and the certification of compliance with ESRD Conditions for Coverage that underlies every Medicare claim submitted by a dialysis facility.

The OIG has conducted multiple large-scale investigations of dialysis providers — including investigations targeting EPO administration practices, dialysate waste documentation, specimen collection and laboratory billing arrangements, and kickback arrangements between dialysis facilities and referring nephrologists. The national dialysis industry's high degree of consolidation and the Medicare-dependence of the dialysis patient population make it a particularly high-profile target for government enforcement.

Service Areas

Corporate Compliance Program Development

We build ESRD-specific corporate compliance programs implementing all seven OIG compliance program elements — with content specifically designed for the compliance risk profile of dialysis operations:

Written compliance policies covering clinical documentation standards, Medicare billing compliance, physician arrangement compliance, exclusion screening, medication administration documentation, and patient referral compliance. Compliance officer designation with appropriate authority, independence, and board reporting access. Role-specific compliance training for clinical staff, billing staff, and leadership. Anonymous compliance hotline with documented intake, investigation, and resolution processes. Annual audit plan targeting the highest-risk billing and documentation areas in the ESRD setting. Consistent disciplinary standards for compliance violations. Response protocols for detected problems, including self-disclosure evaluation.

False Claims Act Risk Assessment

We conduct structured FCA risk assessments for dialysis operators — analyzing current billing and documentation practices for the specific FCA exposure patterns most commonly identified in government enforcement actions involving ESRD facilities.

High-Risk FCA Areas We Assess:

• EPO and ESA Administration Documentation — Erythropoiesis-stimulating agent administration in dialysis patients requires specific documentation of hemoglobin levels, dose adjustments, and clinical rationale for administration decisions. Systematic documentation deficiencies in ESA administration have been the basis for significant FCA settlements in the dialysis industry.

• Dialysate Waste and Medication Billing Accuracy — Billing for dialysis-related medications, including Vitamin D analogs, iron, and other intravenous medications, requires accurate documentation of doses administered. Documentation practices that systematically overstate doses administered create significant FCA exposure.

• Specimen Collection and Laboratory Billing — Arrangements between dialysis facilities and outside laboratories for routine ESRD laboratory testing have been a consistent area of OIG scrutiny, with Anti-Kickback and Stark Law concerns arising from laboratory billing arrangements that benefit from the volume of specimens the dialysis facility provides.

• Physician Arrangement Compliance — Financial relationships between dialysis facilities and the nephrologists who refer patients to them — including medical director compensation, physician office space arrangements, and joint venture structures — must meet Stark Law and Anti-Kickback Statute requirements. We conduct physician arrangement compliance reviews as part of the overall FCA risk assessment.
  

CIA Management

Dialysis operators that have resolved FCA investigations through settlement with the OIG frequently enter Corporate Integrity Agreements that impose specific compliance monitoring, reporting, and certification obligations for periods of three to five years. We provide CIA implementation support — building the compliance infrastructure required by the CIA's specific provisions and managing the reporting and certification obligations throughout the CIA period.